ICOS agonist vopratelimab modulates follicular helper T cells and improves B cell function in common variable immunodeficiency
Clinical Immunology · 2024
DOI: 10.1016/j.clim.2024.110217 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Immunology, 2024. Verfasst von Ali Sepahi und 7 weiteren Autor:innen. Beteiligte Einrichtung: PharmaEssentia Innovation Research Center, Bedford, MA, United States; Concentra Biosciences, LLC, Cambridge, MA, United States. Hauptthemen laut MEDLINE: Common Variable Immunodeficiency, Inducible T-Cell Co-Stimulator Protein, B-Lymphocytes, T Follicular Helper Cells. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 71 Literaturangaben. Gefördert von: Jounce Therapeutics, National Institutes of Health.
Abstract (Originalsprache)
Common variable immunodeficiency (CVID) is an immune defect characterized by hypogammaglobulinemia and impaired development of B cells into plasma cells. As follicular helper T cells (TFH) play a central role in humoral immunity, we examined TFH cells in CVID, and investigated whether an inducible T cell co-stimulator (ICOS) agonist, vopratelimab, could modulate TFH, B cell interactions and enhance immunoglobulin production. CVID subjects had decreased TFH17 and increased TFH1 subsets; this was associated with increased transitional B cells and decreased IgG+ B and IgD-IgM-CD27+ memory B cells. ICOS expression on CVID CD4+ T cells was also decreased. However, ICOS activation of CD4+ T cells by vopratelimab significantly increased total CVID TFH, TFH2, cell numbers, as well as IL-4, IL-10 and IL-21 secretion in vitro. Vopratelimab treatment also increased plasma cells, IgG+ B cells, reduced naïve & transitional B cells and significantly increased IgG1 secretion by CVID B cells. Interestingly, vopratelimab treatment also restored IgA secretion in PBMCs from several CVID patients who had a complete lack of endogenous serum IgA. Our data demonstrate the potential of TFH modulation in restoring TFH and enhancing B cell maturation in CVID. The effects of an ICOS agonist in antibody defects warrants further investigation. This biologic may also be of therapeutic interest in other clinical settings of antibody deficiency.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- PharmaEssentia Innovation Research Center, Bedford, MA, United States; Concentra Biosciences, LLC, Cambridge, MA, United States.
- Department of Medicine, Division of Clinical Immunology, Icahn School of Medicine at Mount Sinai, New York, NY, United States.
- ReNAgade Therapeutics, Cambridge, MA, United States; Concentra Biosciences, LLC, Cambridge, MA, United States.
- AstraZeneca, Cambridge, MA, United States; Concentra Biosciences, LLC, Cambridge, MA, United States.
- NextPoint Therapeutics, Inc., Cambridge, MA, United States; Concentra Biosciences, LLC, Cambridge, MA, United States.
- Crossbow Therapeutics, Cambridge, MA, United States; Concentra Biosciences, LLC, Cambridge, MA, United States.
Förderung
- Jounce Therapeutics
- National Institutes of Health
Zitieren
APA
Sepahi, A., Ho, H. E., Vyas, P., Umiker, B., Kis-Toth, K., Wiederschain, D., Radigan, L., & Cunningham-Rundles, C. (2024). ICOS agonist vopratelimab modulates follicular helper T cells and improves B cell function in common variable immunodeficiency. Clinical Immunology. https://doi.org/10.1016/j.clim.2024.110217
Vancouver
Sepahi A, Ho HE, Vyas P, Umiker B, Kis-Toth K, Wiederschain D, et al. ICOS agonist vopratelimab modulates follicular helper T cells and improves B cell function in common variable immunodeficiency. Clinical Immunology. 2024. doi:10.1016/j.clim.2024.110217
BibTeX
@article{Sepahi2024,
author = {Sepahi, Ali and Ho, Hsi-En and Vyas, Prapti and Umiker, Benjamin and Kis-Toth, Katalin and Wiederschain, Dmitri and Radigan, Lin and Cunningham-Rundles, Charlotte},
title = {ICOS agonist vopratelimab modulates follicular helper T cells and improves B cell function in common variable immunodeficiency},
journal = {Clinical Immunology},
year = {2024},
doi = {10.1016/j.clim.2024.110217}
}
EUVIMED